Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

Literature DB >> 14218553

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

A P DICK, M J GRAYSON, R G CARPENTER, A PETRIE.

Abstract

Entities: Chemical

Keywords: ANEMIA, HEMOLYTIC; CLINICAL RESEARCH; COLITIS, ULCERATIVE; DRUG THERAPY; GASTROINTESTINAL DISEASES; JAUNDICE; SALICYLAZOSULFAPYRIDINE; SKIN MANIFESTATIONS; TOXICOLOGIC REPORT

Mesh：

Substances：
Sulfasalazine

Year: 1964 PMID： 14218553 PMCID： PMC1552152 DOI： 10.1136/gut.5.5.437

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

× No keyword cloud information.

8 in total

1. VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS.

Authors: J H BARON; A M CONNELL; J E LENNARD-JONES
Journal: Br Med J Date: 1964-01-11

2. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis.

Authors: S C TRUELOVE; G WATKINSON; G DRAPER
Journal: Br Med J Date: 1962-12-29

3. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

Authors: J H BARON; A M CONNELL; J E LENNARD-JONES; F A JONES
Journal: Lancet Date: 1962-05-26 Impact factor: 79.321

4. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis.

Authors: J E LENNARD-JONES; A J LONGMORE; A C NEWELL; C W WILSON; F A JONES
Journal: Gut Date: 1960-09 Impact factor: 23.059

5. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis.

Authors: C G MOERTEL; J A BARGEN
Journal: Ann Intern Med Date: 1959-11 Impact factor: 25.391

6. Heinz-body anaemia due to salicylazosulphapyridine.

Authors: A I SPRIGGS; R S SMITH; H GRIFFITH; S C TRUELOVE
Journal: Lancet Date: 1958-05-17 Impact factor: 79.321

7. Results of treatment of ulcerative colitis with salicylazosulfapyridine.

Authors: L M MORRISON
Journal: Gastroenterology Date: 1952-05 Impact factor: 22.682

8. Agranulocytosis associated with sulphasalazine ('Salazopyrin') therapy.

Authors: J L THIRKETTLE; K R GOUGH; A E READ
Journal: Lancet Date: 1963-06-29 Impact factor: 79.321

8 in total

65 in total

Review 1. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

Authors: F Van den Bosch; D Baeten; E Kruithof; F De Keyser; H Mielants; E M Veys
Journal: Ann Rheum Dis Date: 2001-11 Impact factor: 19.103

2. Frontiers in inflammatory bowel disease. The proceedings of a conference sponsored by the McReynolds Foundation. Part II.

Authors: R G Shorter; D A Shephard
Journal: Am J Dig Dis Date: 1975-07

3. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors: F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal: Ann Rheum Dis Date: 2000-06 Impact factor: 19.103

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

1. VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS.

2. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis.

3. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

4. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis.

5. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis.

6. Heinz-body anaemia due to salicylazosulphapyridine.

7. Results of treatment of ulcerative colitis with salicylazosulfapyridine.

8. Agranulocytosis associated with sulphasalazine ('Salazopyrin') therapy.

Review 1. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

2. Frontiers in inflammatory bowel disease. The proceedings of a conference sponsored by the McReynolds Foundation. Part II.

3. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

4. Is mesalamine safe?

5. Ulcerative colitis: current treatment strategies and future prospects.

6. Meta-analysis of the placebo response in ulcerative colitis.

7. Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.

Review 8. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

9. Desensitization for sulfasalazine-induced skin rash in a patient with ulcerative colitis.

10. Medical treatment of ulcerative colitis.